Daily Newsletter

19 October 2023

Daily Newsletter

19 October 2023

Abbott reports 2.6% dip in sales for Q3 2023

The company recorded GAAP EPS of $0.82 and adjusted diluted EPS of $1.14 for the quarter.

RanjithKumar Dharma October 19 2023

Abbott has reported net sales of $10.14bn for the third quarter (Q3) of 2023 against $10.41bn in Q3 last year, down by 2.6%.

Sales dropped because of the expected decrease in Covid-19 testing-related sales compared to the previous year.

Its net earnings for the quarter were $1.436bn, compared to $1.435bn last year, representing a difference of 0.1%.

The company reported GAAP diluted earnings per share (EPS) of $0.82 and adjusted diluted EPS of $1.14 for the quarter.

For the first nine months of the year, the company recorded net sales of $29.86bn versus $33.56bn during the same period last year, a dip of 11%.

The company's net earnings during the period amounted to $4.1bn, representing a 30% decrease from $5.9bn earned during the same period last year.

Abbott anticipates full-year GAAP diluted EPS to range between $3.14 and $3.18. Additionally, adjusted diluted EPS is projected to fall between $4.42 and $4.46.

The company anticipates organic sales growth for the full year 2023, excluding Covid-19 testing-related sales, to remain in the low double digits.

Abbott chairman and CEO Robert Ford said: “The investments we made during the pandemic continue to drive broad-based growth across our underlying base business.

“We're on track to deliver on the financial commitments we set at the beginning of the year and the momentum we're building across the portfolio positions us well as we head into 2024.”

AI will become a key driver of medical device innovation

The medical devices industry is highly regulated and therefore can be slow to adopt new technologies to modernize. However, it is realizing the benefits that AI can bring, and AI is now being used in different areas across the entire value chain. Common use cases include data management, remote surgery, diagnostic and procedural AI assistants, and clinical trial design. GlobalData estimates that the AI in medical devices market is expected to grow at a CAGR of >29% by 2027.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close